Final follow-up of a Phase I dose-ranging study of Bendamustine and Rituximab (BR) in patients with chronic lymphocytic leukemia (CLL) with comorbidities

被引：0
|
作者：
Danilov, Alexey [1 ]
Lewis, Lionel [2 ]
Brown, Jennifer [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Dartmouth Coll, Hanover, NH USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [31] Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis
    Brander, Danielle
    Weinberg, J. Brice
    Friedman, Daphne
    Stewart, Tiffany
    Rizzieri, David
    LEUKEMIA & LYMPHOMA, 2017, 58 : 35 - 37
  • [32] Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study
    Shadman, Mazyar
    Gopal, Ajay K.
    Press, Oliver
    Maloney, David G.
    Mawad, Raya
    Wadsworth, Troy
    Dennie, Trevor W.
    Schultheiss, Karl
    Kojouri, Kiarash
    Kammerer, Britt E.
    Pagel, John M.
    BLOOD, 2016, 128 (22)
  • [33] Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [35] BENDAMUSTINE (B) IN COMBINATION WITH RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/RESISTANT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ITALIAN MULTICENTRE RETROSPECTIVE STUDY
    Iannitto, E.
    Morabito, F.
    Mancuso, S.
    Gentile, M.
    Augello, A.
    Bongarzoni, V.
    Cascavilla, N.
    D'Arco, A.
    Di Renzo, N.
    Fazzi, R.
    Ferrara, F.
    Franco, G.
    Gobbi, M.
    Liardo, E.
    Liberati, A. M.
    Marasca, R.
    Montanini, A.
    Mule, A.
    Musso, M.
    Musto, P.
    Pennese, E.
    Piccin, A.
    Scalabrini, D. Rota
    Sciacca, M.
    Visani, G.
    Abbadessa, V.
    Rigacci, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 323 - 323
  • [36] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Stilgenbauer, Stephan
    Bahlo, Jasmin
    Schweighofer, Carmen D.
    Boettcher, Sebastian
    Staib, Peter
    Kiehl, Michael
    Eckart, Michael J.
    Kranz, Gabriele
    Goede, Valentin
    Elter, Thomas
    Buehler, Andreas
    Winkler, Dirk
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
  • [37] Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Boettcher, Sebastian
    Bahlo, Jasmin
    Schubert, Joeerg
    Pflueger, Karl H.
    Schott, Silke
    Goede, Valentin
    Isfort, Susanne
    von Tresckow, Julia
    Fink, Anna-Maria
    Buehler, Andreas
    Winkler, Dirk
    Kreuzer, Karl-Anton
    Staib, Peter
    Ritgen, Matthias
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Stilgenbauer, Stephan
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) : 3209 - 3216
  • [38] Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
    Shadman, Mazyar
    Munir, Talha
    Robak, Tadeusz
    Brown, Jennifer R.
    Kahl, Brad S.
    Ghia, Paolo
    Giannopoulos, Krzysztof
    Simkovic, Martin
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia A.
    Opat, Stephen S.
    Ciepluch, Hanna
    Greil, Richard
    Hanna, Merit
    Tani, Monica
    Trneny, Marek
    Brander, Danielle
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Tedeschi, Alessandra
    de Guibert, Sophie
    Tumyan, Gayane
    Laribi, Kamel
    Garcia-Marco, Jose A.
    Li, Jian-Yong
    Tian, Tian
    Liu, Yu
    Korolkiewicz, Roman
    Szeto, Andy
    Tam, Constantine S.
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [39] Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
    Stilgenbauer, Stephan
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Cartron, Guillaume
    Hallek, Michael
    Eichhorst, Barbara
    Kozloff, Mark F.
    Giever, Thomas
    Lozanski, Gerard
    Jiang, Yanwen
    Huang, Huang
    Pignataro, Daniela Soriano
    Schary, William
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Salles, Gilles
    HAEMATOLOGICA, 2021, 106 (11) : 2834 - 2844
  • [40] Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
    Flinn, Ian W.
    Berdeja, Jesus G.
    Waselenko, Jamie K.
    Cooper, R. Seth
    Bi, Jia
    Shih, Kent
    Doss, Habib H.
    Dickson, Natalie
    Thompson, Dana S.
    Burris, Howard A., III
    Hainsworth, John D.
    BLOOD, 2010, 116 (21) : 1022 - 1022
12345